Compare Regeneron Pharmaceuticals Inc (REGN) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Global X Defense Tech ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while Global X Defense Tech ETF trades at $60.76. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while Global X Defense Tech ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| REGN | SHLD | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Sector/Thematic |
52-Week High | $812.27 | $78.02 |
52-Week Low | $545.46 | $58.20 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
SHLD trades at $60.03, down slightly by 0.05% with a bearish technical signal from moving averages. The ETF offers exposure to global defense technology companies amid rising military spending trends. Recent news highlights institutional buying interest and geopolitical tailwinds supporting the sector's growth outlook.
The defense technology theme benefits from increased global budgets, but SHLD faces competition from other defense ETFs and valuation concerns. Near-term technical support at $59 could stabilize declines, while resistance at $61 may cap upside. Risks include political shifts and execution challenges among holdings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
